Misplaced Pages

Immune reconstitution inflammatory syndrome
Specialty	Immunology

Immune reconstitution inflammatory syndrome (IRIS) is a condition seen in some cases of HIV/AIDS or immunosuppression, in which the immune system begins to recover, but then responds to a previously acquired opportunistic infection with an overwhelming inflammatory response that paradoxically makes the symptoms of infection worse.

IRIS may also be referred to as immune reconstitution syndrome, immune reconstitution disease, immune recovery disease, and immune restoration disease.

Systemic or local inflammatory responses may occur with improvement in immune function. While this inflammatory reaction is usually self-limited, there is risk of long-term symptoms and death, particularly when the central nervous system is involved.

Management generally involves symptom control and treatment of the underlying infection. In severe cases of IRIS, corticosteroids are commonly used. Important exceptions to using corticosteroids include Cryptococcal meningitis and Kaposi’s sarcoma, as they have been associated with poorer outcomes.

Mechanism

There are two common IRIS scenarios. The first is the “unmasking” of an occult opportunistic infection. The second is the “paradoxical” symptomatic relapse of a prior infection despite microbiologic treatment success. Often in paradoxical IRIS, microbiologic cultures are sterile. In either scenario, there is hypothesized reconstitution of antigen-specific T cell-mediated immunity with activation of the immune system against persisting antigen, whether present as intact organisms, dead organisms, or debris.

In HIV infection and immunosuppression

The suppression of CD4 T cells by HIV (or by immunosuppressive drugs) causes a decrease in the body's normal response to certain infections. Not only does this make it more difficult to fight the infection, it may mean that a level of infection that would normally produce symptoms is instead undetected (subclinical infection). If the CD4 count rapidly increases (due to effective treatment of HIV, or removal of other causes of immunosuppression), a sudden increase in the inflammatory response produces nonspecific symptoms such as fever, and in some cases a worsening of damage to the infected tissue.

Though these symptoms can be dangerous, they also indicate that the body may now have a better chance to defeat the infection. The best treatment for this condition is unknown. In paradoxical IRIS reactions, the events will usually spontaneously get better with time without any additional therapy. In unmasking IRIS, the most common treatment is to administer antibiotic or antiviral drugs against the infectious organism. In some severe cases, anti-inflammatory medications, such as corticosteroids are needed to suppress inflammation until the infection has been eliminated.

Infections most commonly associated with IRIS include Mycobacterium tuberculosis and cryptococcal meningitis. Persons living with AIDS are more at risk for IRIS if they are starting HAARTTooltip HAART for the first time, or if they have recently been treated for an opportunistic infection (OI). It is generally advised that when patients have a low initial CD4 T cell count and OI at the time of their HIV diagnosis, they receive treatment to control the OIs before HAART is initiated approximately two weeks later. This is true for most OIs, except for OIs involving the central nervous system.

In individuals without HIV/AIDS

Since the HIV/AIDS epidemic in the 1980s, IRIS is now mostly associated with the initiation of HIV treatment with highly active antiretroviral therapy (HAART), also referred to as antiretroviral therapy (ART). However, IRIS can still occur in the following conditions that do not involve HIV:

• Solid organ transplant recipients
  • After undergoing solid organ transplant (liver, kidney, pancreas, etc.), patients are prescribed immunosuppressive agents, such as tacrolimus or cyclosporine. These medications target CD4 immune cells, suppressing their function. IRIS in these patients is thought to be due to the pro-inflammatory response after withdrawal of immunosuppressants. Common infections associated with IRIS in these patients are cryptococcosis, cytomegalovirus (CMV), and tuberculosis.
• Neutropenic patients
  • When the absolute neutrophil count (ANC) is less than 500 per microliter, there is an increased risk of fungal and viral opportunistic infections (OI), such as Aspergillus or CMV. While the patient is immunosuppressed, these infections may remain latent and asymptomatic. However, when the ANC improves, the infections may become symptomatic and present as IRIS. Common infections associated with IRIS in these patients are invasive pulmonary aspergillosis and chronic disseminated candidiasis.
• Postpartum patients
  • During pregnancy, the immune system is relatively suppressed to prevent fetal rejections or miscarriages. In the immediate postpartum period (3 to 6 weeks), this process is reversed, resulting in a relative pro-inflammatory state. There is an increased risk of IRIS during this period. Common infections associated with IRIS in these patients include cryptococcosis, human papillomavirus reactivation, herpes virus, tuberculosis, leprosy, viral hepatitis. Flare-ups of autoimmune conditions such as systemic lupus erythematosus and rheumatoid arthritis may also occur during this period.
• Patients on tumor necrosis factor antagonists
  • Patients with chronic inflammatory conditions (Crohn's disease, ulcerative colitis, sarcoidosis, etc.) are often treated with TNF antagonists, such as infliximab, adalimumab, and etanercept. Tumor necrosis factors are critical in macrophage activation and subsequent granuloma formation. Therefore, TNF antagonists impair the host immune response against infections such as tuberculosis. While the patient is taking TNF antagonists, these infections may remain latent and asymptomatic. However, when these medications are discontinued, there may be an associated pro-inflammatory response causing the infection to be uncovered.

In cryptococcal meningitis

IRIS is particularly problematic in cryptococcal meningitis as IRIS is fairly common and can be fatal.

IRIS has been described in immunocompetent hosts who have meningitis caused by Cryptococcus gattii and Cryptococcus neoformans var. grubii, environmental fungi which often affect immunocompetent hosts. Several weeks or even months into appropriate treatment, there is a sudden onset deterioration with worsening meningitis symptoms and progression or development of new neurological symptoms.

Magnetic resonance imaging shows increase in the size of brain lesions, and CSF abnormalities (white cell count, protein, glucose) increase. CSF culture is typically sterile, and there is no increase in CSF cryptococcal antigen titer.

The increasing inflammation can cause brain injury or be fatal.

The general mechanism behind IRIS is increased inflammation as the recovering immune system recognizes the antigens of the fungus as immunosuppression is reversed. Cryptococcal IRIS has three phases:

1. before HAART, with a paucity of cerebrospinal fluid (CSF) inflammation and defects in antigen clearance;
2. during initial HAART immune recovery, with pro-inflammatory signaling by antigen-presenting cells without an effector response; and
3. at IRIS, a cytokine storm with a predominant type-1 helper T-cell interferon-gamma response.

Three clinical predictors of cryptococcal-related paradoxical IRIS risk include:

1. lack of initial CSF pleocytosis (i.e. low CSF white blood cell count);
2. elevated C-reactive protein;
3. failure to sterilize the CSF before immune recovery.

IRIS may be the cause of paradoxically worse outcomes for cryptococcal meningitis in immunocompetent compared with immunocompromised hosts, in whom Cryptococcus neoformans is the usual pathogen. Treatment with systemic corticosteroids during IRIS may be beneficial in preventing death or progressive neurological deterioration. Steroids given to persons with anti-fungal treatment failure / cryptococcal relapse (in whom CSF cultures are not sterile) can be a fatal iatrogenic error.

Signs and symptoms

The clinical presentation of IRIS is variable and typically depends on the underlying OI. Common features that may be present include clinical worsening after starting ART and localized tissue inflammation. A systemic inflammatory response may or may not be present. The majority of IRIS cases occur within 4 to 8 weeks of ART initiation or change. However, there have been reported cases from 3 days to several months or even years after ART initiation.

The following table describes the major and minor presentations in reported underlying OIs.

Diagnosis

The diagnosis of IRIS is clinical. There is no universal definition of IRIS, however there is general consensus that most of the following criteria should be met to make the diagnosis:

• Presence of AIDS with low pretreatment CD4 count, typically <100 cells/microL. An exception is in the setting of Mycobacterium tuberculosis infection, which can be reactivated with CD4 cells >200 cells/microL.
• Decrease in HIV-1 RNA levels from baseline or increase in CD4 count after starting ART
• No evidence of drug-resistant infection, bacterial superinfection, adverse drug reaction, patient non-adherence, or reduced serum drug levels (from drug-drug interactions or malabsorption).
• Clinical symptoms consistent with an inflammatory condition
• Temporal association between initiation of ART and symptom onset

The differential diagnosis of IRIS is broad given its varied presentation. Conditions that can present similarly to IRIS are: adverse drug effects, progression of initial OI caused by medication resistance or patient non-adherence, and development of a new OI.

Management

Mild IRIS

• For mild symptoms, treatment is focused on treating the underlying infection and symptom management. Non-steroidal anti-inflammatory drugs (NSAIDs) may be used to alleviate inflammatory symptoms, such as fever or pain. Abscess drainage, excision of painful and inflamed lymph nodes, and inhaled corticosteroids for bronchospasm from mild pulmonary inflammation may also be used when indicated.

Severe IRIS

• In severe IRIS, symptoms may cause permanent disability or death. Management again includes antimicrobial treatments against the underlying infection. Corticosteroids are the most commonly used intervention in these cases as they work to suppress the inflammatory response seen in IRIS, though there is limited research on their efficacy. Guidelines recommend a risk/benefit analysis prior to starting corticosteroids, especially taking into consideration the patient’s comorbidities. Common adverse effects of corticosteroids are hyperglycemia, hypertension, mental status changes, worsening of an existing infection, and increased risk of a new infection. Important exceptions include cases of Cryptococcal-IRIS with worsening meningitis symptoms (cranial nerve defects, hearing or vision changes) and cases of Kaposi's sarcoma. In these cases, corticosteroids should not be used as they have been shown to worsen outcomes.
• It is recommended to continue ART except in the most severe cases of IRIS. Discontinuing ART may be considered in life-threatening cases of IRIS not improved by corticosteroids, usually in central nervous system-associated IRIS. Stopping ART increases the risk of acquiring new OI and developing IRIS again when restarting ART.

Prognosis

IRIS has a reported mortality rate of 4.5%. Mortality rates vary and depend on the associated OI, degree of immunosuppression, geography, and access to treatment. IRIS affecting the central nervous system has generally been associated with the highest mortality rates (13-75%).

History

IRIS was discovered in the 1980s when physicians noted paradoxical symptomatic worsening of patients being treated for pulmonary tuberculosis and leprosy. There was worsened fever, weight loss, shortness of breath, and fatigue in patients with pulmonary tuberculosis and worsened skin lesions in patients with leprosy. Though the mechanism was unclear at the time, these observations were attributed to a pro-inflammatory state brought on by starting treatment.

In bats recovering from white-nose syndrome

Bats recovering from white-nose syndrome (WNS) may be the first known natural occurrence of IRIS, in a report released by the USGS. WNS is typified by a cutaneous infection of the fungus Pseudogymnoascus destructans during hibernation, when the immune system is naturally suppressed to conserve energy through the winter. This study suggests that bats undergoing an intense inflammation at the site of infection after a return to euthermia is a form of IRIS.

See also

• List of cutaneous conditions
• Jarisch-Herxheimer reaction, another systemic inflammatory syndrome that arises after antimicrobial treatment

References

1. Shelburne SA, Visnegarwala F, Darcourt J, Graviss EA, Giordano TP, White AC, Hamill RJ (March 2005). "Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy". AIDS. 19 (4): 399–406. doi:10.1097/01.aids.0000161769.06158.8a. PMID 15750393. S2CID 2062992.
2. Wolfe C (2023). Post TW (ed.). Immune reconstitution inflammatory syndrome. Waltham, MA: UpToDate.
3. ^ Thapa S, Shrestha U (2022). "Immune Reconstitution Inflammatory Syndrome". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID 33620872. Retrieved 2023-02-09.
4. ^ Brust JC, McGowan JP, Fine SM, Merrick ST, Radix AE, Vail RM, et al. (2021). Management of Immune Reconstitution Inflammatory Syndrome (IRIS). New York State Department of Health AIDS Institute Clinical Guidelines. Baltimore (MD): Johns Hopkins University. PMID 34029021.
5. ^ Bohjanen PR, Boulware DR (2008). "HIV Immune Reconstitution Inflammatory Syndrome". Global HIV/AIDS Medicine. pp. 193–205. doi:10.1016/B978-1-4160-2882-6.50022-8. ISBN 978-1-4160-2882-6.
6. ^ Sun HY, Singh N (August 2009). "Immune reconstitution inflammatory syndrome in non-HIV immunocompromised patients". Current Opinion in Infectious Diseases. 22 (4): 394–402. doi:10.1097/QCO.0b013e32832d7aff. PMID 19483618. S2CID 206001177.
7. ^ Boulware DR, Meya DB, Bergemann TL, Wiesner DL, Rhein J, Musubire A, et al. (December 2010). "Clinical features and serum biomarkers in HIV immune reconstitution inflammatory syndrome after cryptococcal meningitis: a prospective cohort study". PLOS Medicine. 7 (12): e1000384. doi:10.1371/journal.pmed.1000384. PMC 3014618. PMID 21253011.
8. ^ Boulware DR, Bonham SC, Meya DB, Wiesner DL, Park GS, Kambugu A, et al. (September 2010). "Paucity of initial cerebrospinal fluid inflammation in cryptococcal meningitis is associated with subsequent immune reconstitution inflammatory syndrome". The Journal of Infectious Diseases. 202 (6): 962–970. doi:10.1086/655785. PMC 2924457. PMID 20677939.
9. Lane M, McBride J, Archer J (August 2004). "Steroid responsive late deterioration in Cryptococcus neoformans variety gattii meningitis". Neurology. 63 (4): 713–714. doi:10.1212/01.wnl.0000134677.29120.62. PMID 15326249. S2CID 42308361.
10. Einsiedel L, Gordon DL, Dyer JR (October 2004). "Paradoxical inflammatory reaction during treatment of Cryptococcus neoformans var. gattii meningitis in an HIV-seronegative woman". Clinical Infectious Diseases. 39 (8): e78–e82. doi:10.1086/424746. PMID 15486830.
11. Ecevit IZ, Clancy CJ, Schmalfuss IM, Nguyen MH (May 2006). "The poor prognosis of central nervous system cryptococcosis among nonimmunosuppressed patients: a call for better disease recognition and evaluation of adjuncts to antifungal therapy". Clinical Infectious Diseases. 42 (10): 1443–1447. doi:10.1086/503570. JSTOR 4484756. PMID 16619158.
12. Wiesner DL, Boulware DR (December 2011). "Cryptococcus-Related Immune Reconstitution Inflammatory Syndrome(IRIS): Pathogenesis and Its Clinical Implications". Current Fungal Infection Reports. 5 (4): 252–261. doi:10.1007/s12281-011-0064-8. PMC 3289516. PMID 22389746.
13. Musubire AK, Meya BD, Mayanja-Kizza H, Lukande R, Wiesner LD, Bohjanen P, R Boulware RD (June 2012). "Challenges in diagnosis and management of Cryptococcal immune reconstitution inflammatory syndrome (IRIS) in resource limited settings". African Health Sciences. 12 (2): 226–230. doi:10.4314/ahs.v12i2.23. PMC 3462548. PMID 23056032.
14. Walker NF, Scriven J, Meintjes G, Wilkinson RJ (February 2015). "Immune reconstitution inflammatory syndrome in HIV-infected patients". HIV/AIDS: Research and Palliative Care. 7: 49–64. doi:10.2147/HIV.S42328. PMC 4334287. PMID 25709503.
15. Breton G, Duval X, Estellat C, Poaletti X, Bonnet D, Mvondo Mvondo D, et al. (December 2004). "Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy". Clinical Infectious Diseases. 39 (11): 1709–1712. doi:10.1086/425742. PMID 15578375.
16. Lortholary O, Fontanet A, Mémain N, Martin A, Sitbon K, Dromer F (July 2005). "Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France". AIDS. 19 (10): 1043–1049. doi:10.1097/01.aids.0000174450.70874.30. PMID 15958835. S2CID 20343917.
17. ^ Haddow LJ, Easterbrook PJ, Mosam A, Khanyile NG, Parboosing R, Moodley P, Moosa MY (November 2009). "Defining immune reconstitution inflammatory syndrome: evaluation of expert opinion versus 2 case definitions in a South African cohort". Clinical Infectious Diseases. 49 (9): 1424–1432. doi:10.1086/630208. PMID 19788360.
18. ^ Shelburne SA, Hamill RJ, Rodriguez-Barradas MC, Greenberg SB, Atmar RL, Musher DW, et al. (May 2002). "Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy". Medicine. 81 (3): 213–227. doi:10.1097/00005792-200205000-00005. PMID 11997718. S2CID 39597801.
19. ^ Müller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M (April 2010). "Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis". The Lancet. Infectious Diseases. 10 (4): 251–261. doi:10.1016/S1473-3099(10)70026-8. PMC 4183458. PMID 20334848.
20. Bahr N, Boulware DR, Marais S, Scriven J, Wilkinson RJ, Meintjes G (December 2013). "Central nervous system immune reconstitution inflammatory syndrome". Current Infectious Disease Reports. 15 (6): 583–593. doi:10.1007/s11908-013-0378-5. PMC 3883050. PMID 24173584.
21. "White-Nose Syndrome Bat Recovery May Present Challenges Similar to Those in Some Recovering AIDS Patients" (Press release). USGS. November 19, 2012. Archived from the original on April 26, 2020. Retrieved February 22, 2020.
22. Meteyer CU, Barber D, Mandl JN (November 2012). "Pathology in euthermic bats with white nose syndrome suggests a natural manifestation of immune reconstitution inflammatory syndrome". Virulence. 3 (7): 583–588. doi:10.4161/viru.22330. PMC 3545935. PMID 23154286.

Further reading

• Chan RK, Chio MT, Koh HY (2018). "Cutaneous Manifestations of HIV Infection". In Bolognia J, Schaffer JV, Cerroni L (eds.). Dermatology. Elsevier Health Sciences. p. 1378. ISBN 978-0-7020-6342-8. OCLC 1016978099. Immune Reconstitution Inflammatory Syndrome (IRIS)

• HIV/AIDS
• Immune system disorders
• Virus-related cutaneous conditions
• Syndromes